Differential DNA methylation analysis of SUMF2 , ADAMTS5 , and PXDN provides novel insights into colorectal cancer prognosis prediction in Taiwan

• Published in: World journal of gastroenterology : WJG 2022-02, Vol.28 (8), p.825-839
• Main Authors: Su, Jing-Quan, Lai, Pin-Yu, Hu, Pei-Hsuan, Hu, Je-Ming, Chang, Pi-Kai, Chen, Chao-Yang, Wu, Jia-Jheng, Lin, Yu-Jyun, Sun, Chien-An, Yang, Tsan, Hsu, Chih-Hsiung, Lin, Hua-Ching, Chou, Yu-Ching
• Format: Article
• Language: English
• Subjects: ADAMTS5 Protein - genetics; Cohort Studies; Colorectal Neoplasms - genetics; Colorectal Neoplasms - pathology; Colorectal Neoplasms - therapy; CpG Islands - genetics; Deoxyribonucleosides; DNA Methylation; Humans; Peroxidases - genetics; Prognosis; Purine Nucleosides; Retrospective Cohort Study; Sulfatases - genetics; Taiwan
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v28.i8.825

Patients with colorectal cancer (CRC) undergo surgery, as well as perioperative chemoradiation or adjuvant chemotherapy primarily based on the tumor-node- metastasis (TNM) cancer staging system. However, treatment responses and prognostic outcomes of patients within the same stage vary markedly. The potential use of novel biomarkers can improve prognostication and shared decision making before implementation into certain therapies. To investigate whether , , and methylation status could be associated with CRC prognosis. We conducted a Taiwanese cohort study involving 208 patients with CRC recruited from Tri-Service General Hospital and applied the candidate gene approach to identify three genes involved in oncogenesis pathways. A methylation-specific polymerase chain reaction (MS-PCR) and EpiTYPER DNA methylation analysis were employed to detect methylation status and to quantify the methylation level of candidate genes in tumor tissue and adjacent normal tissue from participants. We evaluated , , and methylation as predictors of prognosis, including recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS), using a Cox regression model and Kaplan-Meier analysis. We revealed various outcomes related to methylation and prognosis. Significantly shorter PFS and OS were associated with the CpG_3+CpG_7 hypermethylation of from tumor tissue compared with CpG_3+CpG_7 hypomethylation [hazard ratio (HR) = 2.24, 95% confidence interval (CI) = 1.03-4.85 for PFS, HR = 2.56 and 95%CI = 1.08-6.04 for OS]. By contrast, a significantly longer RFS was associated with CpG_2 and CpG_13 hypermethylation of from normal tissue compared with CpG_2 and CpG_13 hypomethylation [HR (95%CI) = 0.15 (0.03-0.71) for CpG_2 and 0.20 (0.04-0.97) for CpG_13]. The relationship between the methylation status of and the prognosis of CRC did not reach statistical significance. Our study found that CpG_3+CpG_7 hypermethylation of from tumor tissue was associated with significantly shorter PFS and OS compared with CpG_3+CpG_7 hypomethylation. CpG_2 and CpG_13 hypermethylation of from normal tissue was associated with a significantly longer RFS compared with CpG_2 and CpG_13 hypomethylation. These methylation-related biomarkers which have implications for CRC prognosis prediction may aid physicians in clinical decision-making.